|
Colon Cancer – Pipeline Review, H1 2012
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 219 seiten | |||||||||
| Inhalt der Studie: |
Introduction
Global Markets Direct’s, 'Colon Cancer - Pipeline Review, H1 2012', provides an overview of the Colon Cancer therapeutic pipeline. This report provides information on the therapeutic dev.....
Introduction Global Markets Direct’s, 'Colon Cancer - Pipeline Review, H1 2012', provides an overview of the Colon Cancer therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. 'Colon Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Colon Cancer. - A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Colon Cancer pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Highlights Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Colon Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Colon Cancer therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. [Studien Infos ausblenden] |
|||||||||||
|
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Colon Cancer Overview 11 Therapeutics Development 12 An Overview of Pipeline Products for Colon Cancer 12 Colon Cancer Therapeutics under Development by Companies 14 Colon Cancer Therapeutics under Investigation by Universities/Institutes 21 Late Stage Products 26 Comparative Analysis 26 Mid Clinical Stage Products 27 Comparative Analysis 27 Early Clinical Stage Products 28 Comparative Analysis 28 Discovery and Pre-Clinical Stage Products 29 Comparative Analysis 29 Colon Cancer Therapeutics – Products under Development by Companies 30 Colon Cancer Therapeutics – Products under Investigation by Universities/Institutes 37 Companies Involved in Colon Cancer Therapeutics Development 43 Kyowa Hakko Kirin Co., Ltd. 43 Eli Lilly and Company 44 Albany Molecular Research, Inc. 45 Labopharm Inc. 46 Celltrion, Inc. 47 Prolexys Pharmaceuticals, Inc. 48 Bio-Path Holdings, Inc. 49 ZIOPHARM Oncology, Inc. 50 Fox Chase Cancer Center 51 ImClone Systems Incorporated 52 Enzon Pharmaceuticals, Inc. 53 Alfacell Corporation 54 Access Pharmaceuticals, Inc. 55 Alchemia Limited 56 EntreMed, Inc. 57 GW Pharmaceuticals plc 58 Enzo Biochem, Inc. 59 ImmunoCellular Therapeutics, Ltd. 60 Lorus Therapeutics Inc 61 Bio-Bridge Science, Inc. 62 Bionomics Limited 63 Neuren Pharmaceuticals Limited 64 Cleveland BioLabs, Inc. 65 OncoVista Innovative Therapies, Inc. 66 Compugen Ltd. 67 Patrys Limited 68 Cosmo Pharmaceuticals S.p.A 69 Critical Outcome Technologies Inc. 70 Curis, Inc. 71 Telik, Inc. 72 Dendreon Corporation 73 Green Cross Corporation 74 CrystalGenomics, Inc. 75 Sareum Holdings plc 76 Rexahn Pharmaceuticals, Inc. 77 SymBio Pharmaceuticals Limited 78 MabVax Therapeutics, Inc. 79 Antisense Pharma GmbH 80 Immupharma Plc 81 Actinium Pharmaceuticals, Inc. 82 Indena S.p.A. 83 InterMed Discovery GmbH 84 Provecs Medical GmbH 85 Alethia Biotherapeutics Inc. 86 NormOxys, Inc. 87 MacroGenics, Inc. 88 OncoMed Pharmaceuticals, Inc. 89 Conatus Pharmaceuticals Inc. 90 ProNAi Therapeutics, Inc. 91 Mersana Therapeutics, Inc. 92 Affichem 93 Jennerex Biotherapeutics, Inc. 94 Advenchen Laboratories, LLC 95 Myriad Pharmaceuticals, Inc. 96 Xencor, Inc. 97 Vaccinogen, Inc. 98 Globeimmune, Inc. 99 APEIRON Biologics AG 100 Etubics Corporation 101 NewLink Genetics Corporation 102 Taiwan Liposome Company 103 TVAX Biomedical, LLC 104 Viventia Biotechnologies Inc. 105 Phytomedics, Inc. 106 Merus B.V. 107 Pique Therapeutics 108 Cellceutix Pharmaceuticals, Inc. 109 Celtic Pharmaceutical Holdings L.P. 110 ISA Pharmaceuticals B.V. 111 ImQuest Life Sciences 112 TAU Therapeutics, LLC 113 Immunovative Therapies, Ltd. 114 Oncozyme Pharma Inc. 115 CytomX, LLC. 116 Colon Cancer – Therapeutics Assessment 117 Assessment by Monotherapy Products 117 Assessment by Combination Products 118 Assessment by Route of Administration 119 Assessment by Molecule Type 121 Drug Profiles 124 Erbitux - Drug Profile 124 OncoVAX - Drug Profile 125 Rosuvastatin - Drug Profile 127 5-Fluorouracil + Leucovorin Calcium + Oxaliplatin + Bevacizumab - Drug Profile 129 Fluorouracil + Leucovorin + Oxaliplatin - Drug Profile 131 Carboplatin + 5-Fluorouracil + Leucovorin - Drug Profile 133 Fluorouracil + Leucovorin - Drug Profile 135 FOLFOX-4 - Drug Profile 136 FOLFOX-4 + Cetuximab - Drug Profile 138 Fluorouracil + Leucovorin Calcium - Drug Profile 140 FOLFIRI - Drug Profile 141 Tegafur-Uracil - Drug Profile 143 Fluorouracil + Levamisole Hydrochloride - Drug Profile 144 Fluorouracil + Leucovorin + Levamisole - Drug Profile 145 FOLFOX-4 - Drug Profile 147 Bevacizumab + XELOX - Drug Profile 148 Fluorouracil + Irinotecan + Leucovorin - Drug Profile 150 Bevacizumab + FOLFOX-4 - Drug Profile 152 FOLFOX-4 - Drug Profile 154 Cetuximab + Fluorouracil + Irinotecan + Leucovorin - Drug Profile 156 Fluorouracil + Semustine + Vincristine - Drug Profile 158 Oxaliplatin + Folinic Acid + 5-Fluorouracil - Drug Profile 160 UFT + Leucovorin Calcium - Drug Profile 162 Celecoxib + Fluorouracil + Leucovorin Calcium - Drug Profile 164 Fluorouracil + Leucovorin Calcium - Drug Profile 166 OxCap + Panitumumab - Drug Profile 167 OxMdG + Panitumumab - Drug Profile 169 5-Fluorouracil + Folinic Acid + CPT-11 - Drug Profile 171 Xeloda - Drug Profile 173 Uracil + Tegafur + Leucovorin - Drug Profile 174 carboplatin + fluorouracil + leucovorin - Drug Profile 175 Oxaliplatin + FluoroPyrimidine + Panitumumab - Drug Profile 177 Bevacizumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin Calcium + Oxaliplatin - Drug Profile 179 C225 + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium - Drug Profile 181 Oxaliplatin + Leucovorin Calcium + Fluorouracil + Celecoxib - Drug Profile 183 Bevacizumab + 5-Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 185 Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin - Drug Profile 188 Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin - Drug Profile 190 Bevacizumab + Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 192 Capecitabine + Oxaliplatin - Drug Profile 194 Capecitabine + Oxaliplatin - Drug Profile 195 palonosetron - Drug Profile 196 Oxaliplatin + Leucovorin + Fluorouracil - Drug Profile 197 FOLFOX 4 - Drug Profile 198 Colon Cancer Therapeutics – Drug Profile Updates 199 Colon Cancer Therapeutics – Discontinued Products 200 Colon Cancer Therapeutics - Dormant Products 201 Colon Cancer – Product Development Milestones 208 Featured News & Press Releases 208 Appendix 215 Methodology 215 Expert Panel Validation 216 Contact Us 216 Disclaimer 216 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Number of Products Under Development for Colon Cancer, H1 2012 15 Products under Development for Colon Cancer – Comparative Analysis, H1 2012 16 Number of Products under Development by Companies, H1 2012 18 Number of Products under Development by Companies, H1 2012 (Contd..1) 19 Number of Products under Development by Companies, H1 2012 (Contd..2) 20 Number of Products under Development by Companies, H1 2012 (Contd..3) 21 Number of Products under Development by Companies, H1 2012 (Contd..4) 22 Number of Products under Development by Companies, H1 2012 (Contd..5) 23 Number of Products under Investigation by Universities/Institutes, H1 2012 25 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 26 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 27 Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 28 Comparative Analysis by Late Stage Development, H1 2012 29 Comparative Analysis by Mid Clinical Stage Development, H1 2012 30 Comparative Analysis by Early Clinical Stage Development, H1 2012 31 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 32 Products under Development by Companies, H1 2012 33 Products under Development by Companies, H1 2012 (Contd..1) 34 Products under Development by Companies, H1 2012 (Contd..2) 35 Products under Development by Companies, H1 2012 (Contd..3) 36 Products under Development by Companies, H1 2012 (Contd..4) 37 Products under Development by Companies, H1 2012 (Contd..5) 38 Products under Development by Companies, H1 2012 (Contd..6) 39 Products under Investigation by Universities/Institutes, H1 2012 40 Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 41 Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 42 Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 43 Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 44 Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 45 Kyowa Hakko Kirin Co., Ltd., H1 2012 46 Eli Lilly and Company, H1 2012 47 Albany Molecular Research, Inc., H1 2012 48 Labopharm Inc., H1 2012 49 Celltrion, Inc., H1 2012 50 Prolexys Pharmaceuticals, Inc., H1 2012 51 Bio-Path Holdings, Inc., H1 2012 52 ZIOPHARM Oncology, Inc., H1 2012 53 Fox Chase Cancer Center, H1 2012 54 ImClone Systems Incorporated, H1 2012 55 Enzon Pharmaceuticals, Inc., H1 2012 56 Alfacell Corporation, H1 2012 57 Access Pharmaceuticals, Inc., H1 2012 58 Alchemia Limited, H1 2012 59 EntreMed, Inc., H1 2012 60 GW Pharmaceuticals plc, H1 2012 61 Enzo Biochem, Inc., H1 2012 62 ImmunoCellular Therapeutics, Ltd., H1 2012 63 Lorus Therapeutics Inc, H1 2012 64 Bio-Bridge Science, Inc., H1 2012 65 Bionomics Limited, H1 2012 66 Neuren Pharmaceuticals Limited, H1 2012 67 Cleveland BioLabs, Inc., H1 2012 68 OncoVista Innovative Therapies, Inc., H1 2012 69 Compugen Ltd., H1 2012 70 Patrys Limited, H1 2012 71 Cosmo Pharmaceuticals S.p.A, H1 2012 72 Critical Outcome Technologies Inc., H1 2012 73 Curis, Inc., H1 2012 74 Telik, Inc., H1 2012 75 Dendreon Corporation, H1 2012 76 Green Cross Corporation, H1 2012 77 CrystalGenomics, Inc., H1 2012 78 Sareum Holdings plc, H1 2012 79 Rexahn Pharmaceuticals, Inc., H1 2012 80 SymBio Pharmaceuticals Limited, H1 2012 81 MabVax Therapeutics, Inc., H1 2012 82 Antisense Pharma GmbH, H1 2012 83 Immupharma Plc, H1 2012 84 Actinium Pharmaceuticals, Inc., H1 2012 85 Indena S.p.A., H1 2012 86 InterMed Discovery GmbH, H1 2012 87 Provecs Medical GmbH, H1 2012 88 Alethia Biotherapeutics Inc., H1 2012 89 NormOxys, Inc., H1 2012 90 MacroGenics, Inc., H1 2012 91 OncoMed Pharmaceuticals, Inc., H1 2012 92 Conatus Pharmaceuticals Inc., H1 2012 93 ProNAi Therapeutics, Inc., H1 2012 94 Mersana Therapeutics, Inc., H1 2012 95 Affichem, H1 2012 96 Jennerex Biotherapeutics, Inc., H1 2012 97 Advenchen Laboratories, LLC, H1 2012 98 Myriad Pharmaceuticals, Inc., H1 2012 99 Xencor, Inc., H1 2012 100 Vaccinogen, Inc., H1 2012 101 Globeimmune, Inc., H1 2012 102 APEIRON Biologics AG, H1 2012 103 Etubics Corporation, H1 2012 104 NewLink Genetics Corporation, H1 2012 105 Taiwan Liposome Company, H1 2012 106 TVAX Biomedical, LLC, H1 2012 107 Viventia Biotechnologies Inc., H1 2012 108 Phytomedics, Inc., H1 2012 109 Merus B.V., H1 2012 110 Pique Therapeutics, H1 2012 111 Cellceutix Pharmaceuticals, Inc., H1 2012 112 Celtic Pharmaceutical Holdings L.P., H1 2012 113 ISA Pharmaceuticals B.V., H1 2012 114 ImQuest Life Sciences, H1 2012 115 TAU Therapeutics, LLC, H1 2012 116 Immunovative Therapies, Ltd., H1 2012 117 Oncozyme Pharma Inc., H1 2012 118 CytomX, LLC., H1 2012 119 Assessment by Monotherapy Products, H1 2012 120 Assessment by Combination Products, H1 2012 121 Assessment by Stage and Route of Administration, H1 2012 123 Assessment by Molecule Type, H1 2012 126 Colon Cancer Therapeutics – Drug Profile Updates 202 Colon Cancer Therapeutics – Discontinued Products 203 Colon Cancer Therapeutics – Dormant Products 204 Colon Cancer Therapeutics – Dormant Products (Contd..1) 205 Colon Cancer Therapeutics – Dormant Products (Contd..2) 206 Colon Cancer Therapeutics – Dormant Products (Contd..3) 207 Colon Cancer Therapeutics – Dormant Products (Contd..4) 208 Colon Cancer Therapeutics – Dormant Products (Contd..5) 209 Colon Cancer Therapeutics – Dormant Products (Contd..6) 210 List of Figures Number of Products under Development for Colon Cancer, H1 2012 15 Products under Development for Colon Cancer – Comparative Analysis, H1 2012 16 Products under Development by Companies, H1 2012 17 Products under Investigation by Universities/Institutes, H1 2012 24 Late Stage Products, H1 2012 29 Mid Clinical Stage Products, H1 2012 30 Early Clinical Stage Products, H1 2012 31 Discovery and Pre-Clinical Stage Products, H1 2012 32 Assessment by Monotherapy Products, H1 2012 120 Assessment by Combination Products, H1 2012 121 Assessment by Route of Administration, H1 2012 122 Assessment by Stage and Route of Administration, H1 2012 123 Assessment by Molecule Type, H1 2012 124 Assessment by Stage and Molecule Type, H1 2012 125 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
